Company profile
Ticker
ARTV
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
863614316
ARTV stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
29 Aug 24
8-K
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
29 Aug 24
S-8
Registration of securities for employees
22 Jul 24
8-K
Amendments to Articles of Incorporation or Bylaws
22 Jul 24
424B4
Prospectus supplement with pricing info
19 Jul 24
EFFECT
Notice of effectiveness
19 Jul 24
S-1MEF
Registration of additional securities for an S-1
18 Jul 24
CERT
Certification of approval for exchange listing
18 Jul 24
8-A12B
Registration of securities on exchange
16 Jul 24
S-1/A
IPO registration (amended)
15 Jul 24
Latest ownership filings
4
Heather Raymon
13 Sep 24
4
Thorsten Graef
13 Sep 24
4
Christopher Horan
13 Sep 24
4
Neha Krishnamohan
13 Sep 24
4
Jennifer Bush
13 Sep 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
3 Sep 24
SC 13G
venBio Global Strategic Fund III, L.P.
1 Aug 24
SC 13G
Venrock Healthcare Capital Partners III, L.P.
1 Aug 24
SC 13G
5AM Ventures VI, L.P.
1 Aug 24
SC 13D
RA CAPITAL MANAGEMENT, L.P.
29 Jul 24
Financial summary
Quarter (USD) | Jun 24 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 34.51 mm | 34.51 mm | ||||
Cash burn (monthly) | 5.40 mm | (no burn) | ||||
Cash used (since last report) | 16.30 mm | n/a | ||||
Cash remaining | 18.21 mm | n/a | ||||
Runway (months of cash) | 3.4 | n/a |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Sep 24 | Neha Krishnamohan | Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 50,000 |
12 Sep 24 | Bush Jennifer | Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 72,799 |
12 Sep 24 | Heather Raymon | Common Stock | Grant | Acquire A | No | No | 0 | 10,000 | 0.00 | 10,000 |
12 Sep 24 | Thorsten Graef | Common Stock | Grant | Acquire A | No | No | 0 | 20,000 | 0.00 | 20,000 |
12 Sep 24 | Christopher Horan | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 25,000 |
News
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $23 Price Target
30 Aug 24
Artiva Biotherapeutics Q2 EPS $(22.00) Down From $(14.09) YoY
29 Aug 24
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
13 Aug 24
Needham Initiates Coverage On Artiva Biotherapeutics with Buy Rating, Announces Price Target of $23
13 Aug 24
Wedbush Initiates Coverage On Artiva Biotherapeutics with Outperform Rating, Announces Price Target of $18
13 Aug 24
Press releases
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
10 Sep 24
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
29 Aug 24
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
18 Jul 24